Zhitong Finance App News, Hengrui Pharmaceutical (01276) announced that recently, the company's subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Pharmaceutical Clinical Trial Approval Notice” for HRS-2189 tablets and will conduct clinical trials in the near future.

HRS-2189 tablets are a novel KAT6 inhibitor. It is intended to treat advanced malignant tumors by inhibiting histone lysine acetylation levels, regulating the expression of various downstream cancer genes and thereby exerts an antitumor effect. Currently, no drugs with the same target have been approved for marketing at home or abroad. Up to now, the total R&D investment for HRS-2189 film-related projects is about 55.3 million yuan (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.